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Introduction
Figure 1: AEG-1 WT and global KO mice were given a single intraplantar injection of 50% CFA in mineral oil to model chronic 
inflammation. (a) AEG-1 WT mice displayed a higher degree of mechanical hypersensitivity at all time points, post injection, compared 
to AEG-1 KO mice. (b) AEG-1 WT mice displayed a higher degree of thermal sensitivity on day 4, post injection,  compared to AEG-1 
KO. (c) AEG-1 WT mice appear to show higher paw edema, measured 3 days following CFA injection, compared to AEG-1 KO mice. • Transgenic global knockout of AEG-1 appears to provide protection from 
CFA induced  mechanical hypersensitivity, thermal sensitivity, and paw 
edema.
• AEG-1 expression levels do not differ between C57BL6/J mice treated with 
CFA or Control at 3 days post injection.
• Transgenic global knockout of AEG-1 appears to provide enhanced 
recovery from paclitaxel induced  mechanical hypersensitivity and cold 
sensitivity.
• AEG-1 expression levels do not differ between C57BL6/J mice treated with 
8mg/Kg paclitaxel or Control at 3 days post injection cycle.
Future:
• Optimized IHC studies to assess AEG-1 and NF-κB protein localization in 
mice PAG, SpC, and DRG of various pain models.
• Performing a time course and collecting tissues at earlier time points to 
assess potential changes in AEG-1 expression in neuronal tissues.
• Assess the effects of  analgesic drugs (such as morphine and gabapentin) on 
the anti-nociceptive phenotype displayed by AEG-1 KO mice.
Results
• Astrocyte Elevated Gene 1 (AEG-1) was first identified as an 
upregulated gene in primary human fetal astrocytes infected with 
HIV-1 and has since been observed to have elevated expression 
levels in various CNS diseases1. 
• AEG-1 acts as a scaffolding protein and mediates inflammation via 
direct protein-protein interaction with p65 (NF-κB) 1.
• AEG-1 global knockout mice have been shown to be more resistant 
to inflammation compared to wild type littermates1.
• Chemotherapy Induced Peripheral Neuropathy (CIPN) may develop 
in cancer patients undergoing treatment and may result in them 
having to switch to less effective drug regiments or ceasing 
treatment entirely2.
• Current FDA approved drugs for chronic pain and neuropathy show 
modest efficacy and have severe side effects such as drug misuse 
and addiction3.
Hypothesis
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Methods
• AEG-1 acts as a mediator of inflammation via a NF-κB-dependent 
molecular mechanism. Therefore, making it a potential target for 
treatment in inflammatory pain.
• Therefore, we decided explore the role of AEG-1 in mouse models 
of Chronic Inflammatory pain and Chemotherapy Induced 
Peripheral Neuropathy (CIPN). 
• We hypothesized that deletion of  AEG-1 gene would result in 
protection from nociception in our chosen mouse models of pain
Results
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Animals:
• C57BL6/J male and female mice, 8-14 weeks old (n = 5).
• AEG-1 WT or global knockout male and female mice on C57BL6/J 
background, 8-14 weeks old (n = 6). 
Models:
• Chronic Inflammatory Pain was induced via Freund's Complete 
Adjuvant (CFA). Mice received 20 μL, i.pl, injections of 50% CFA 
or vehicle. 
• Chemotherapy Induced Peripheral Neuropathy was induced via
Paclitaxel (Taxol®). Mice received 8 mg/kg, i.p, injections of 
paclitaxel or vehicle. (Previously described by Toma, et. al 4)
Assays:
• Von Frey: Assess mechanical hypersensitivity.
• Acetone Test: Assess cold sensitivity.
• qRT-PCR: Assess quantity of specific mRNA transcripts.
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AEG-1 WT and global KO mice were given 4 periodic intraperitoneal injections of Paclitaxel in a Kolliphore solution (8 mg/kg) 
to model chemotherapy-induced peripheral neuropathy. AEG-1 KO mice displayed enhanced recovery from Paclitaxel-induced 
(a) mechanical hypersensitivity and (b) cold sensitivity at later time points compared to WT littermates.
AEG-1 in Chronic Inflammatory Pain
AEG-1 in CIPN 
AEG-1 mrRNA expression was measured in the Peri Aquaductal Gray (PAG), 
L4-6 spinal cord (SpC), and corresponding Dorsal Root Ganglia (DRG). 
These tissues are involved in neural pain processing pathways. C57Bl6/J mice 
were injected with either 4 x 8 mg/kg Paclitaxel (a-c) or 50% CFA (d-f), 
sacrificed 3 day post final injection, and tissues collected. No difference 
detected between drug treated mice compared to vehicle.
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